scholarly journals Decrease of Atherosclerosis Markers and Oxidative Stress After 1 Year Administration of Omega-3 Fatty Acids Supplements in Patients with Metabolic Syndrome

2014 ◽  
Vol 21 (3) ◽  
pp. 175-183
Author(s):  
Andreea Dragomir ◽  
Emila Rusu ◽  
Mihaela Posea ◽  
Gabriela Radulian

AbstractBackground and Aims: To assess the impact of 1 year administration of omega-3 fatty acids supplements on oxidative stress parameters and atherosclerosis progression. Material and Methods: A total of 284 patients with metabolic syndrome, aged 61±6.7 years, without clinical evidence of atherosclerosis were allocated to 2 groups, matched by sex and age: group A (140 patients) - diet according to ESC/EASD recommendations; group B (144 patients) - the same diet + capsules of fish oil (1g eicosapentanoic acid, 1g docosahexanoic acid, 0,1g a-tocopherol acetate). Body fat (BF) was measured by bioimpedance analysis. For oxidative stress evaluation we used the FormOx systems monitor on a blood drop and for progression of atherosclerosis the intima-media thickness (IMT) at common carotid artery. Patients were evaluated at baseline, after 6 months and 1 year. Results: IMT significantly decreased in group B vs group A at 1 year (p<0.0001) and was correlated with %BF (p<0.001), waist-to-hip ratio (WHR) (p=0.002), leptin (p< 0.001), adiponectin (p<0.05), leptin/adiponectin ratio (p< 0.001) and oxidative stress (p<0.001). Conclusions: One year administrations of omega-3 PUFA enriched diet reduces cardiovascular risk of metabolic syndrome patients, resulting in a significant decrease of oxidative stress and atherosclerosis progression.

2016 ◽  
Vol 32 (2) ◽  
pp. 519-528 ◽  
Author(s):  
Lara M. Gomes ◽  
Milena Carvalho-Silva ◽  
Letícia J. Teixeira ◽  
Joyce Rebelo ◽  
Isabella T. Mota ◽  
...  

Author(s):  
C. Srinivasa ◽  
K. La Kshminarayan ◽  
V. Srinivas ◽  
B. V. S. Chandrasekhar

Background: Current treatment with statins has become an integral part of vascular diseases but monotherapy has a significant residual event rate. Due to particularly one of the factor associated with atherogenic lipid phenotype that is characterized by a low high-density lipoprotein (HDL) cholesterol and increase in non-HDL cholesterol like Low-Density Lipoprotein (LDL). Omega-3 Fatty acids have demonstrated a preventiverole in primary and, particularly secondary cardiovascular diseases.  Hence this study was planned to compare the efficacy of Atorvastatin alone with Atorvastatin and Omega-3 fatty acids in treatment in hyperlipidaemia patients. Methods: The study was comparative, randomized, and prospective and open labeled conducted in MI patients. A total of 100 patients were selected based on inclusion and exclusion criteria. They were divided randomly into two Groups (Group–A and Group-B). Group-A was given Atorvastatin 10mg/day and Group-B was given Atorvastatin 10mg/day and Omega-3 fatty acids 600mg/day for 6 months. Follow up was done every month and efficacy was measured by assessing the lipoprotein levels in serum. Results: The results were compared before treatment and after 6 months treatment.The levels were significantly decreased Total Cholesterol (TC), LDL, Low-Density Lipoprotein (VLDL), Triglycerides (TG) and HDL levels were increased in Group–A and Group-B. When these results compared between two Groups the HDL levels were increased also it shown high significance (<0.001) but there were no significance changes in other cholesterol levels. Conclusion: The present study results showed that Atorvastatin and Omega-3 fatty acids treatment was more effective than Atorvastatin alone treatment in improving HDL-C levels from base line and it may have a additive effect in major coronary artery diseases.


2014 ◽  
Vol 29 (1) ◽  
pp. 185-192 ◽  
Author(s):  
Camila S. Model ◽  
Lara M. Gomes ◽  
Giselli Scaini ◽  
Gabriela K. Ferreira ◽  
Cinara L. Gonçalves ◽  
...  

2019 ◽  
Vol 149 ◽  
pp. 104462 ◽  
Author(s):  
Javad Heshmati ◽  
Mojgan Morvaridzadeh ◽  
Saman Maroufizadeh ◽  
Abolfazl Akbari ◽  
Mahsa Yavari ◽  
...  

2013 ◽  
Vol 115 (12) ◽  
pp. 1492-1498 ◽  
Author(s):  
Laurie Joumard-Cubizolles ◽  
Cécile Gladine ◽  
Nicolas Gérard ◽  
Christophe Chambon ◽  
Patrick Brachet ◽  
...  

2020 ◽  
Vol 45 (8) ◽  
pp. 805-811
Author(s):  
José A. Valle Flores ◽  
Juan E. Fariño Cortéz ◽  
Gabriel A. Mayner Tresol ◽  
Juan Perozo Romero ◽  
Miquel Blasco Carlos ◽  
...  

Chronic kidney disease (CKD) is an increasingly common public health problem that increases the risk of death because of cardiovascular complications by 2–3 times compared with the general population. This research concerns a prospective, randomized, double-blind study in patients with CKD undergoing hemodialysis. The participants were assigned to 1 of 2 groups: the study group (group A; 46 patients) received 4 capsules (2.4 g) of omega-3 fatty acids daily during the 12-week intervention, while patients in the control group (group B; 47 patients) received 4 capsules of paraffin oil. The patients’ general characteristics, nutritional indicators, renal disease markers and inflammatory markers (C-reactive protein, interleukin (IL)-6, IL-10, and tumour necrosis factor alpha (TNF-α)) were evaluated. No differences were found between the general characteristics of the patients (P < 0.05), and no differences were shown in the nutritional indicators and markers of kidney disease (P < 0.05). Patients in group A showed significant decreases in levels of C-reactive protein, IL-6, TNF-α, and the IL-10/IL-6 ratio after 12 weeks of supplementation (P < 0.05). Patients in group B did not show any significant changes in concentrations of inflammatory markers during the intervention (P < 0.05). In conclusion, oral supplementation with omega-3 fatty acids produces a significant decrease in the concentrations of inflammation markers in patients with chronic kidney disease on hemodialysis. Novelty Oral supplementation with omega-3 fatty acids produced significant decreases in the concentrations of inflammation markers. This supplementation could be given to patients with uremic syndrome and coronary heart disease to reduce cardiovascular risk.


Author(s):  
Abroo Fatima Qazi ◽  
Din Muhammad Shaikh

Aims: The current study investigated the effects of polyunsaturated Omega-3-fatty acids on underlying mechanism linked with diabetes in streptozocin induced type 2 diabetic Wistar rats. Study Design:  Experimental analytical Study. Place and Duration of Study: The study was conducted at Isra University Hyderabad and Sindh Agricultural University, Tandojam between November 2016 and November 2018. Methodology: Seventy-five Wistar rats were assorted to five groups (15 rats per group): negative control group A and positive control group B and experimental groups C, D and E. Rats within group B,C,D, and E were injected with streptozocin (65 mg/kg body weight) to induce diabetes. Experimental groups C, D and E received Omega-3-fatty acid supplemented food in 0.3 g, 0.4 g and 0.5 g/kg bodyweight dosage for 12 weeks, respectively. Results: Omega-3-fatty acids treated rats showed significant decrease in blood glucose level and rise in serum insulin as compared to positive control group (p-value = 0.001). At the same time, they showed significantly increased expression of insulin gene along with transcription factors: PDX1 and NKX6.1 as compared to group A (p-value = 0.001). Conclusion: It is concluded that O3FAs reduces insulin resistance in Streptozocin-induced diabetic Wistar rats by modulating the transcription factors essential for insulin gene expression.


Sign in / Sign up

Export Citation Format

Share Document